Q2 2026 saw a 17.2% NAV total return in CHF, net profit of CHF 451 mn, and strong outperformance versus the Nasdaq Biotechnology Index. Twelve new investments and three M&A deals highlighted portfolio activity, while a revised dividend policy targets a 3-5% yield.Original document: BB Biotech AG [B…
Net profit rebounded to CHF 451mn in Q2 2026, with NAV outperforming the Nasdaq Biotech Index. Portfolio diversification and strategic M&A activity drove results, while a disciplined capital allocation framework was reinforced by a 3-5% dividend yield and share buybacks.Original document: BB Biotec…
NAV rose 17.2% in Q2 2026, with net profit of CHF 451 million and strong outperformance versus the NBI. Twelve new investments and three M&A transactions enhanced portfolio diversification. A refined dividend policy and share buyback program support disciplined capital allocation.Original document…
BB BIOTECH AG / Key word(s): Results / Half yearBB Biotech AG publishes its interim report and revises its dividend policy24-Jul-2026 / 07:00 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.The i…
BB BIOTECH AG/ Key word(s): Half Year ReportBB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning24.07.2026 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Media release as at July 24, 2026BB Biotech Q2 20…
